Noteworthy ETF Inflows: DFAC, CVX, WFC, MRK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Source: NASDAQ.COM
DFAC Stock Performance: DFAC's stock has a 52-week range with a low of $28.39 and a high of $36.66, currently trading at $34.37, which is useful for technical analysis when compared to the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) operate like stocks but involve buying and selling units that can be created or destroyed based on investor demand, impacting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 119.090
Low
95.00
Averages
119.53
High
139.00
Current: 119.090
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Merck Acquires TARGAN to Expand Poultry Business
- Acquisition Agreement: Merck Animal Health announced the acquisition of biodevice solutions developer TARGAN, with the transaction expected to close in Q3 2026, enhancing its competitive position in the commercial poultry market despite undisclosed financial terms.
- Technology Integration: The acquisition will add TARGAN's automated gender identification device, WingScan, to Merck's portfolio, improving its technological capabilities in the poultry industry to meet market demands for efficient vaccination solutions.
- Vaccine Technology Innovation: TARGAN's ocular spray technology for administering respiratory and other vaccines to newly hatched chicks enhances Merck's diversity and effectiveness in animal health solutions, addressing critical health needs in poultry.
- Shareholder Relationship: Founded in 2015, TARGAN has counted Merck as a major shareholder since 2017, and this acquisition further solidifies their strategic partnership, indicating ongoing investment in the animal health sector.
See More
Merck Animal Health Acquires TARGAN to Enhance Poultry Portfolio
- Acquisition Agreement: Merck Animal Health has announced a definitive agreement to acquire TARGAN, enhancing its biodevice solutions in the poultry sector, with the transaction expected to close in the third quarter of 2026, thereby solidifying Merck's market position in animal health.
- Technology Expansion: The acquisition will expand Merck's poultry portfolio with TARGAN's WingScan technology, an automated chick sex-sorting system capable of processing up to 160,000 chicks per hour, significantly improving efficiency and accuracy in poultry sorting.
- Vaccination Technology Enhancement: The deal also introduces high-speed precision ocular spray technology for administering vaccines to day-old chicks, enhancing Merck's device development capabilities across multiple animal species and increasing its competitive edge in the market.
- Investment Background: Merck has been an investor in TARGAN since 2017 and is one of its largest shareholders, making this acquisition a deepening of its investment and reflecting the company's commitment to the growth potential in the poultry industry.
See More
U.S. Accelerates Response to New World Screwworm Outbreak
- Outbreak Threat: The potential widespread outbreak of the New World screwworm could pose a multi-billion-dollar threat to the U.S. beef industry, which is already facing economic anxiety due to near-record high beef prices exacerbated by ongoing drought conditions.
- Funding Support: The USDA plans to distribute $100 million earlier than expected for new technologies to combat the screwworm threat, demonstrating the government's commitment to agricultural security amid rising concerns.
- Staff Shortages: The USDA is operating with 25% fewer animal health experts than at the start of Trump's second term, which could hinder rapid response efforts, although the agency claims this has not affected its response measures.
- Accelerated Treatments: The FDA has issued 12 emergency use authorizations since last September, allowing for the expedited use of screwworm treatments, reflecting the urgency and coordination of government efforts to address the outbreak.
See More
GSK's $10.6 Billion Nuvalent Acquisition to Rebuild Cancer Drug Portfolio
- Massive Acquisition: GSK's $10.6 billion acquisition of U.S. company Nuvalent marks its largest deal to date, aimed at rebuilding its cancer drug business to fend off competition from AstraZeneca and Roche, with the deal expected to close in Q3.
- Strategic Restructuring: This acquisition aligns with CEO Luke Miels' strategic plan to expand GSK's presence in oncology, compensating for the loss incurred from a decade-old asset swap with Novartis, and is projected to help the company achieve its £40 billion sales target by 2031.
- Intensified Market Competition: The acquisition price reflects a 40% premium over Nuvalent's closing price, indicating strong market interest in its late-stage oncology assets, with analysts estimating a peak sales potential of $3 billion to $4 billion, which could offset the impact of patent expirations on HIV drug sales.
- Future Challenges: While GSK's return to oncology is seen as a strategic correction, analysts caution that the acquired assets may not possess
See More
New World Screwworm Invasion Exacerbates Rising Beef Prices
- Beef Price Surge: The invasion of the New World screwworm has led to a 12.9% year-over-year increase in beef prices, despite a 1.27% decline in May, indicating a persistent upward trend that adds economic pressure on consumers.
- Supply Chain Crisis: The U.S. cattle herd has reached a 75-year low, and the arrival of the screwworm further disrupts ranchers' expansion plans, leading to tight beef supplies and anticipated price increases that will affect consumer purchasing power.
- Increased Demand for Substitutes: Consumers are turning to cheaper meat alternatives like chicken and pork in response to rising beef prices, and while beef demand remains at a 40-year high, this substitution trend may intensify as prices continue to rise.
- Significant Economic Impact: Cattle ranchers face additional labor and veterinary costs, which are expected to significantly impact producers' profits, ultimately passing these costs onto consumers and potentially leading to further increases in grocery beef prices.
See More
Phibro Animal Health Corporation Earnings Analysis
- Core Business Growth: Phibro Animal Health Corporation reported adjusted earnings per share of $0.76 for fiscal Q3 2026, an 18.75% increase from $0.64 in the prior year, exceeding market expectations by 5.92%, indicating strong execution in its core Animal Health segment.
- Strong Revenue Performance: The company achieved a 10.3% year-over-year revenue growth to $383.5 million in Q3, surpassing consensus by 6.26%, with net sales in the Animal Health segment rising 13% to $291.2 million, driven by robust demand for medicated feed additives and vaccines.
- Margin Improvement: Despite a 6% increase in cost of goods sold, gross profit rose 20.2% year-over-year to $125.6 million, with gross margin expanding by 271 basis points to 32.8%, reflecting improvements in product mix and operational execution that helped offset cost pressures.
- Optimistic Future Outlook: Management updated fiscal 2026 guidance, expecting net sales in the range of $1.46 to $1.50 billion, implying 14% growth, and adjusted earnings per share projected between $2.98 and $3.10, representing a 45% improvement over fiscal 2025, showcasing confidence in continued Animal Health execution.
See More
Merck Acquires TARGAN to Expand Poultry Business
- Acquisition Agreement: Merck Animal Health announced the acquisition of biodevice solutions developer TARGAN, with the transaction expected to close in Q3 2026, enhancing its competitive position in the commercial poultry market despite undisclosed financial terms.
- Technology Integration: The acquisition will add TARGAN's automated gender identification device, WingScan, to Merck's portfolio, improving its technological capabilities in the poultry industry to meet market demands for efficient vaccination solutions.
- Vaccine Technology Innovation: TARGAN's ocular spray technology for administering respiratory and other vaccines to newly hatched chicks enhances Merck's diversity and effectiveness in animal health solutions, addressing critical health needs in poultry.
- Shareholder Relationship: Founded in 2015, TARGAN has counted Merck as a major shareholder since 2017, and this acquisition further solidifies their strategic partnership, indicating ongoing investment in the animal health sector.
See More
Merck Animal Health Acquires TARGAN to Enhance Poultry Portfolio
- Acquisition Agreement: Merck Animal Health has announced a definitive agreement to acquire TARGAN, enhancing its biodevice solutions in the poultry sector, with the transaction expected to close in the third quarter of 2026, thereby solidifying Merck's market position in animal health.
- Technology Expansion: The acquisition will expand Merck's poultry portfolio with TARGAN's WingScan technology, an automated chick sex-sorting system capable of processing up to 160,000 chicks per hour, significantly improving efficiency and accuracy in poultry sorting.
- Vaccination Technology Enhancement: The deal also introduces high-speed precision ocular spray technology for administering vaccines to day-old chicks, enhancing Merck's device development capabilities across multiple animal species and increasing its competitive edge in the market.
- Investment Background: Merck has been an investor in TARGAN since 2017 and is one of its largest shareholders, making this acquisition a deepening of its investment and reflecting the company's commitment to the growth potential in the poultry industry.
See More
U.S. Accelerates Response to New World Screwworm Outbreak
- Outbreak Threat: The potential widespread outbreak of the New World screwworm could pose a multi-billion-dollar threat to the U.S. beef industry, which is already facing economic anxiety due to near-record high beef prices exacerbated by ongoing drought conditions.
- Funding Support: The USDA plans to distribute $100 million earlier than expected for new technologies to combat the screwworm threat, demonstrating the government's commitment to agricultural security amid rising concerns.
- Staff Shortages: The USDA is operating with 25% fewer animal health experts than at the start of Trump's second term, which could hinder rapid response efforts, although the agency claims this has not affected its response measures.
- Accelerated Treatments: The FDA has issued 12 emergency use authorizations since last September, allowing for the expedited use of screwworm treatments, reflecting the urgency and coordination of government efforts to address the outbreak.
See More
GSK's $10.6 Billion Nuvalent Acquisition to Rebuild Cancer Drug Portfolio
- Massive Acquisition: GSK's $10.6 billion acquisition of U.S. company Nuvalent marks its largest deal to date, aimed at rebuilding its cancer drug business to fend off competition from AstraZeneca and Roche, with the deal expected to close in Q3.
- Strategic Restructuring: This acquisition aligns with CEO Luke Miels' strategic plan to expand GSK's presence in oncology, compensating for the loss incurred from a decade-old asset swap with Novartis, and is projected to help the company achieve its £40 billion sales target by 2031.
- Intensified Market Competition: The acquisition price reflects a 40% premium over Nuvalent's closing price, indicating strong market interest in its late-stage oncology assets, with analysts estimating a peak sales potential of $3 billion to $4 billion, which could offset the impact of patent expirations on HIV drug sales.
- Future Challenges: While GSK's return to oncology is seen as a strategic correction, analysts caution that the acquired assets may not possess
See More
New World Screwworm Invasion Exacerbates Rising Beef Prices
- Beef Price Surge: The invasion of the New World screwworm has led to a 12.9% year-over-year increase in beef prices, despite a 1.27% decline in May, indicating a persistent upward trend that adds economic pressure on consumers.
- Supply Chain Crisis: The U.S. cattle herd has reached a 75-year low, and the arrival of the screwworm further disrupts ranchers' expansion plans, leading to tight beef supplies and anticipated price increases that will affect consumer purchasing power.
- Increased Demand for Substitutes: Consumers are turning to cheaper meat alternatives like chicken and pork in response to rising beef prices, and while beef demand remains at a 40-year high, this substitution trend may intensify as prices continue to rise.
- Significant Economic Impact: Cattle ranchers face additional labor and veterinary costs, which are expected to significantly impact producers' profits, ultimately passing these costs onto consumers and potentially leading to further increases in grocery beef prices.
See More
